bluuebunny/crossref_metadata_2025_split huggingface dataset:
Epidemiologic characteristics of breast cancer (BC) in Asian Indian and Pakistani population living in the US compared to US white population in SEER database from 1988 to 2002
Authors: Abraham J. , Hossain A. , Sehbai A. 
Published: March 2020

10657 Background: It is estimated that South East Asian population comprises about 1.5% of the total US population and is rapidly growing. BC is the most common cancer in the US-based Indian/Pakistani female population (38%) as reported in the SEER database. This is the first study reporting different epidemiologic characteristics of BC in this population. Methods: From 1988, Indian and Pakistani population with cancer diagnosis was reported separately. Frequency sessions were performed and epidemiologic parameters for BC were calculated regarding age, marital status, stage, grade, laterality, nodal involvement, menopausal status and hormone receptor status. Results: BC comprises about 19% of all cancers reported in US-based Indian and Pakistani population from SEER database. A total of 804 cases of BC were reported in this group in SEER database from 1988 to 2002. BC is the most common cancer (38%) in US-based Indian and Pakistani female population. In comparison, WHO data from 2002 shows that it is the leading cancer in Pakistani females (34%) and second leading cancer in Indian females (19%). BC is more common in this ethnic group than White female (38% vs 32%, p < 0.01) as reported in SEER database. Table shows the comparative studies of different variables of BC between Indian/Pakistani and US White female reported in SEER database. Conclusion: US-based Indian and Pakistani female population is diagnosed with BC at a younger age than US White population. BC tends to express more receptor positivity. A significant number of females are under 50 at the time of diagnosis. More studies in this subset of patients will help in developing screening and educational intervention in this rapidly growing population. [Table: see text] No significant financial relationships to disclose.
Non-pegylated liposomal doxorubicin and docetaxel as front line treatment in HER2-neu negative metastatic breast cancer: Safety and efficacy results
Authors: Cals L. , Nouyrigat P. , Tchiknavorian X. , Dohollou N. , Bertrand F. , Bressac C. , Gomez P. , Facchini T. , Besset M. , Gligorov J. 
Published: March 2020

10659 Background: First line docetaxel (D) and doxorubicin (DXR) yield up to 55% response rates in controlled studies, in relapse situation for patients who have received anthracyclin in adjuvant setting, with the risk to run on cardiotoxicity regarding anthracyclin cumulative dose.The objective of the study is to determine efficacy and tolerance of Myocet (M) and D as frontline chemotherapy in her2-neu negative metastatic breast cancer (MBC) patients (pts) who have received anthracyclin in adjuvant setting. Methods: Eligible pts were above 18 years, with MBC relapsing at least 12 month after anthracyclin given in adjuvant setting. WHO = 0–1-2, normal left ejection fraction (LEF), measurable targets, cumulative dose of DXR or epirubicin or mitoxantron previously administred respectively under 300, 600, 75 mg/m2. Ongoing hormonotherapy or radiotherapy had to be stop at least 4 weeks before treatment: M = 60 mg/m2 was given as 90 minutes infusion, followed by D = 75 mg/m2 given as 60 minutes infusion, the both 21 days cycles for 6 cycles. Clinical adverse event review, haematology was performed each cycle, LEF each two cycles, tumor assessment, at day 50 and day 120. Results: Between 04/04 and 05/05: 21 pts with median age 55 (33–72) entered the study. All pts were metastatic (liver 10 pts, bone 9, lung 4, soft tissue 2, skin 2, pleural 1, multiples 6). Premenopausal 6 pts , negative oestrogen receptor: 5 pts. A total of 108 MD infusion has been given, infusions delayed 11, omitted 1, reduced dose 15. Use of neutrophils growth factors 11 pts. No treatment related death has been reported. Grade 3/4 toxicity: febrile neutropenia 6 pts (28%), thrombocytopenia 1, alopecia 21, nausea-vomiting 0, gastritis 1, dental infection 1, one cardiac heart failure grade 3 was observed 6 month after the end of 9 cycles of MD, responsive to angiotensin conversion inhibitor. Efficacy: 10 partials responses, 5 completes responses and 2 progressive disease. RR = 71% Binomial 95% CI (53–85). Conclusions: MD is clinically well tolerated with however 28 % grade 3/4 neutropenia and a large use of neutrophils growth factors, no life threatening aplasia was observed. The high response rate had to be confirm with the safety results at the end of the accrual (50 pts planed). No significant financial relationships to disclose.
Multicenter phase II study of liposomal doxorubicin (M) and docetaxel (T) as neoadjuvant treatment in patients with stage II - III breast cancer
Authors: Modolell A. , Mayordomo MD J. I. , Garcia-Bueno J. M. , Machengs I. , Alvarez I. , Centelles M. , Palombo H. , Burillo M. , Yubero A. , Murillo L. , Andrés R. 
Published: March 2020

10662 Background: T and M is a very active chemotherapy regimen for breast cancer. M has been shown to be as effective as doxorubicin at same doses while reducing the cardiotoxicity and causing less myelosuppression. This study was designed to evaluate clinical and pathological response rate (RR) and toxicity after induction chemotherapy in patient with breast cancer. Methods: Patients with histological confirmation of breast cancer (stage II-III and inflammatory), age > 18 years, left ventricular eject fraction > 45% and adequate bone marrow, renal and hepatic function were included in the study. Prior systemic therapy or radiotherapy and surgery for breast cancer were not allowed. Treatment: T (75 mg/m2) iv and M (75 mg/m2) iv, every 21 days during 4 cycles, followed by surgery. Results: To date 59 patients have been enrolled; 50 were included in this interim analysis, with a median age of 52 years old (28–76), ECOG PS 0, 88.0%; ECOG PS 1, 12.0%; breast location: right, 52.0%; peri-postmenopausal status, 44.9%. Positive hormonal receptor status was 63.3%. Histology was ductal carcinoma in 84.0%. Patients received a total of 188 cycles (median 4, range 2–4). Median relative dose intensity was 99% for T and for M. Efficacy: Nine patients were non-evaluable (7 on treatment, 1 consent withdrawal and 1 lost of follow-up). Of 41 evaluable patients, 5 achieved complete response (CR) (12.2%), 26 partial response (PR)(63.4%), 9 stable disease (SD) (22.0%) and 1 progressive disease (PD) (2.4%), resulting in a clinical response rate (RR) of 75.6% (95% CI: 62.5–88.7%). Surgery was performed in 40 patients: six (15.0%) of them had pathological (p) CR, 25 (62.5%) pPR, 9 (22.5%) pSD resulting in a pathological RR of 77.5% (95% CI: 64.6–90.4%). Median of time to progression and overall survival has not been achieved yet. Hematological toxicities grades III/IV per patient were neutropenia (14%), thrombocytopenia (4%), leukopenia (2%), anemia (2%) and febrile neutropenia (12%). Non-hematological grade III/IV toxicities per patient were asthenia (6%), nausea / vomiting (4%) and infection (4%). Conclusions: T and M every 21 days during 4 cycles as induction chemotherapy in stage II and III breast cancer is an active and well tolerated treatment. No significant financial relationships to disclose.
Clinical presentation and outcomes of 2,924 early breast cancer patients (br.ca. pts) treated in a single institution in a 10-year period with a long follow up
Authors: Galligioni E. , Triolo R. , Lucenti A. , Ferro A. , Frisinghelli M. , Ambrosini G. , Murgia V. , Micciolo R. 
Published: March 2020

10669 Background: A consecutive series of br.ca. pts, treated between Jan 1st 1990 to Dec 31st 1999 in our Department, is the basis of our retrospective study, aimed to create a data base on routinary clinical management of early br.ca. pts, to which compare similar series and literature data. Methods: All Clinical Records were reviewed and computerized. Disease free and overall survival were estimated using the product-limit method of Kaplan and Meier. The log-rank test was used to compare prognosis between different subgroups. Results: Among 2924 consecutive br.ca. pts, 836 were younger than 50 years (med. age 44) and 2088 older (med. age 63). Regional nodes were negative (N−) in 1754, positive (N+) in 1027 and unknown in the remaining pts. So, 2593 pts were stage I-II and 301 stage IIIA-B. Hormonal Receptor status (available on 2560 pts) was positive for Estrogen (ER+) in 2021 pts and for Progesterone (PgR+) in 1649 pts. Moreover, 1571 pts were ER+Pgr+, 539 ER-PgR−, 78 ER-PgR+ and 461 ER+PgR−. HER2 was overexpressed in 262/1426 (18%) pts. Tumor grading (available on 2176 cases) was G1–2 in 1411 and G3–4 in 765 cases. After surgery, 731 pts received adjuvant Tamoxifen, 507 pts CMF ± Antracyclines chemotherapy, 434 pts both chemotherapy and Tamoxifen and 958 pts none. (no therapy data are available for the remaining 334 pts). At a median f.up of 9.8 years, 993/2924 pts (33.9%) have recurred, (med. DFS 137 mos) with a 5, 10 and 15 y probability of recurrence of 26, 44 and 63% respectively. Corresponding figures of recurrence for N− pts were 14, 30 and 50% (med. DFS 168 mos), while for N+ pts were 41, 61 and 77% (med DFS 81 mos). For younger N+ pts treated with chemotherapy, the 5 years probability of recurrence was 34% while it was 24% for older ER+ pts treated with hormonal therapy. So far, 794/2924 (27.5%) pts have died, with a 5, 10 and 15 y probability of death of 13, 27 and 41%. This was 5, 16 and 28% for N- pts and 22, 41 and 56% for N+ pts. For younger N+ pts treated with chemotherapy, the 5 y probability of death was 14%, as it was for older ER+ pts treated with Tamoxifen. Conclusions: Although this data are not yet conclusive, it appears that large part of the clinical improvements reported in clinical trials may be achieved in the routine management of breast cancer pts. No significant financial relationships to disclose.
Circulating tumour markers and time to progression in the chemotherapy treatment of metastatic breast cancer
Authors: Ruiz-Lopez-tejada M. , Tejedor-Cabrera L. , Iradi-Martinez C. 
Published: March 2020

10674 Background: Monitoring the response to the chemotherapy treatment (CT) in metastatic breast cancer (MBC) by circulating tumour markers (CTM) remains under investigation. We have previosly shown that early lack of biological progression of 4 CTM (1 oncofetal: CEA, 2 mucin related: CA 15.3,CA 549 and cytokeratin 18–19: TPA), predicts anatomic disease control - concordance nearly 100% for every CTM- during CT of MBC (E.J.C. Suppl Oct 2005, Vol 3 Abst 415- ECCO 13). The aim is to evaluate whether the biological behaviour predicts time till progression (TTP), as reliable parameter of the quality of response (QR). Methods: In 106 consecutive courses of different schedules of CT given along 3 years in our Hospital to 55 patients with progressive MBC, we conducted a prospective trial analysing these 4 CTM every 3 weeks before CT infusions and performing CTM concentration / time curves. TTP was calculated by Kaplan Meier method -SPSS 11-. Bio kinetic change has been defined as a lineal slope that includes 2 early and consecutive changes of at least 25% of CTM start value. The analysis covered 604 cycles, 405 curves and 2417 marker determinations. Results: Ninety six per cent of the cases have progressed after their CT courses. In CTM expressing diseases, and sometimes after a no more than 3 weeks paradoxical period, three biological patterns could be detected according to directional possibilities: progressive elevation (Bio P), progressive download (Bio R) and stabilization -without bio kinetic change- (Bio S). Table shows the TTP median values in the different group of cases with the same CTM Bio response patterns; Biological Patterns and TTP Kaplan Meier curves will be shown as a Poster at the meeting. Conclusions: In CTM expressing tumours and taking into account simple kinetics criteria, the dynamic analysis of CTM before infusions can early estimates TTP, adding complemmentary information to the disease control prediction in the evaluation of the QR during the CT of MBC. [Table: see text] No significant financial relationships to disclose.
Identification of estrogenically synthesized LRP16 as an ERα coactivator and its role in ERα-positive breast cancer
Authors: Han W. , Zhao Y. , Wu Z. , Mu Y. , Yu L. , Meng Y. , Huang K. , Zang L. , Li Q. 
Published: March 2020

10676 Background: Aberrant ERα activity is linked to genesis and malignant progression of breast cancer through direct target gene activation or repression. A complex network of coregulatory proteins is largely believed to determine the transcriptional activity of ERα. LRP16 was identified previously to be an estrogen (E2) responsive gene, but its function involving in conferring estrogen signalling pathway is not clear. Methods: Endogenous LRP16 expression in MCF-7 cells was stably suppressed by retrovirus-mediated small interference RNA (siRNA). The effects of LRP16 expression on E2-stimulated growth and invasive ability of MCF-7 cells were determined in vitro and in vivo assays. The effects of LRP16 expression on ERα transactivation were determined by luciferase assays. The interaction of LRP16 and ERα was examined by GST pull-down and coimmunopricipitation (CoIP) assays. Northern blot and Western blot were used to detect the mRNA and protein levels of ER target genes in LRP16-inhibited MCF-7 cells. The LRP16 expression levels in primary breast cancer were detected by Northern blot. Results: Fristly, LRP16 expression was characterized to be dependent on estrogen activities. Then, LRP16 was identified to be an estrogen-independent ERα cofactor in ER-positive breast cancer cells and demonstrate that LRP16 is an essential coactivator to ERα-mediated transactivation in an estrogen-dependent manner. Suppression of LRP16 expression in ER-positive breast cancer cells specifically inhibits the transcription of ER upregulated genes, results in the increase of E-cadherin expression through ER mediation. In vitro and in vivo data demonstrate that suppression of LRP16 inhibits the ability of estrogen-stimulated proliferation and invasiveness of ER-positive breast cancer cells. The pathological and clinical characteristics of human breast cancer includining ER/PR-positiveness, tumor diameter and the involvement of axillary lymphoid nodes were tightly linked with the LRP16 gene expression level. Conclusions: These results establish a mechanistic link between estrogen receptor status, its coactivator LRP16, and progression of ER-positive breast cancers, and may provide a novel antiestrogenic target for the therapy of ER positive breast cancer. No significant financial relationships to disclose.
Capecitabine (X) plus vinorelbine (N) as second-line therapy in Chinese patients (pts) with metastastic breast cancer (MBC)
Authors: Xu B. , Tian L. , Wu Q. , Zhou M. , Wang H. , Tong Z. , Li H. , Li L. , Hu G. , Shi J. 
Published: March 2020

10679 Background: Breast cancer is one of the most common malignancies among Chinese women and the incidence continues to rise, particularly in large cities such as Shanghai. X monotherapy is consistently effective and very well tolerated in pretreated MBC. N is also commonly used in this indication. In several studies, the combination of X + N led to response rates ranging from 43–67% in first-line MBC. As there are few data on this combination in pretreated MBC, we evaluated the efficacy and safety of X + N in Chinese pts with MBC refractory to anthracycline or taxane treatment in a phase II trial. Methods: 77 pts of a planned population of 60 pts were enrolled between Feb 2003 and Nov 2004. All pts had measurable MBC (WHO) recurrent after anthracycline or taxane treatment, Karnofsky PS ≥60, adequate bone marrow, renal and hepatic function. Pts received 3-weekly cycles of oral X 1000mg/m2 bid d1–14 + i.v. N 25mg/m2 d1&8, for at least 2 cycles. Pts with progressive disease went off study while those with complete response (CR), partial response (PR), or stable disease (SD) continued treatment for a maximum of 6 cycles. Results: Baseline characteristics of the 77 pts evaluable to date: median age 51 years (range 29–68); median Karnofsky PS 90 (range 70–100). Previous chemotherapy was: anthracycline (87%), paclitaxel/docetaxel (52%). Principal tumor sites were: lung (40%), liver (39%), lymph nodes (33%), thoracic wall (12%), breast (7%), other (3%). All pts received at least 2 cycles, 20 received 4 cycles and 47 received 6 cycles. The overall response rate was 22%, including 5 CR and 12 PR. At a median follow-up of 6 months (95% CI, 4.2–9.0), the median time to progression (TTP) is 6 months (95% CI, 3.5–9.0). The most common (≥10% pts) treatment-related grade 1/2 adverse events were: HFS (16%), nausea (12%), and SGPT abnormality (10%). Most adverse events improved or resolved after dose adjustment and/or suitable treatments. There were very few grade 3/4 adverse events, the most common being leucopenia (12%). Conclusions: X + N is active in pretreated MBC and its efficacy is confirmed in this study in Chinese pts. The combination is also well tolerated. No significant financial relationships to disclose.
Phase II feasibility of concurrent docetaxel and post mastectomy radiation after four cycles of AC chemotherapy in patients with high risk operable breast cancer: A trial of the Cancer Research Group Pakistan
Authors: Shah I. H. , Shaharyar A. , Shahid A. , Hafeez M. , Perveen S. , Jameel A. , Shabbir K. , Randhawa I. , Gilani J. A. , Masood A. I. , Javed A. A. 
Published: March 2020

10684 Background: Sequential use of docetaxel after four cycles of AC chemotherapy delays the postoperative radiation and can compromise loco-regional control. This delay can be avoided by starting radiotherapy concurrent with the docetaxel. We evaluated the feasibility of concurrent docetaxel and radiation therapy to chest wall and peripheral lymphatics after four cycles of AC chemotherapy. The preliminary results were reported in ASCO 2005 (Abstract 858). Methods: Females between 18–50 years, T2-T3 lesions, four or more positive nodes and hormone receptor negative tumors were eligible. Patients were enrolled after MRM. Four cycles of AC at 60/600 mg/m2 were followed by four cycles of docetaxel at 75mg/m2 every 21-days. Concurrent radiation to chest wall and peripheral lymphatics was started with the third cycle of docetaxel. A dose of 50 Gy in 5 weeks or equivalent was delivered. Successful completion of treatment in 18 out of 20 or 25 out of 30 patients was chosen as an index of feasibility. CTC version 2.0 of NCI and RTOG/EORTC Late Radiation Morbidity Scoring Scheme was used. Results: All the 30 enrolled patients successfully completed the planned treatment. Radiation was completed within 6 months of surgery in 27(90%) of the patients. Febrile neutropenia was seen in 5(16.7%). Grade-3 neutropenia and diarrhea in 8(26.7%) and 6(20%) respectively. Grade-3 dermatitis in the radiated area was seen in 2(6.7%) and grade-2 in 5(16.7%). Late toxicity included grade-2 skin atrophy and telangiectasia in radiated area in 6(20%) each. At a median follow up of 20 months (range 9–25 months) two local recurrences and two systemic relapses have been seen. Conclusion: This treatment schedule is feasible and safe in patients with high-risk operable breast cancer. It allows delivery of post mastectomy radiation within 6 months of surgery in patients undergoing sequential AC-docetaxel chemotherapy. No significant financial relationships to disclose.
Intrahepatic mitomycin C as treatment of breast cancer hepatic metastasis
Authors: Demey W. , Wildiers H. , Maleux G. , Clement P. , Heye S. , Debruyne P. , Van Oosterom A. , Paridaens R. 
Published: March 2020

10690 Background: Because of increasing survival due to improving systemic treatment, liver metastasis represents a major and increasing cause of death in women with metastatic breast cancer. Regional treatment is an attractive option in the treatment of liver metastases. We reviewed the tolerability and efficacy of intrahepatic administration of mitomycin C (MMC) performed in our institution. Patients with only or predominant liver metastasis were eligible, independent of previous chemotherapy for metastatic breast cancer. Methods: In a unicentric protocol we reviewed retrospectively all patients (n = 11) who received intrahepatic MMC for liver metastasis of breast cancer between January 2000 and July 2005 in the University Hospital Leuven. MMC was administered as a bolus of 6 mg in 50 ml saline directly into the right and left hepatic arteries by transcatheter technique. The procedure was performed by an interventional radiologist. Patients were hospitalised for 24 hours. In patients with severe liver function disturbances or more than six administrations of MMC a dose reduction was applied. Results: All treated patients were reviewed. The median age was 52 years (range, 36–61). Most patients were heavily pre-treated with a median of 4 systemic chemotherapy regimens (range, 1–5). Treatment was well tolerated, no grade 3 or 4 adverse events were reported. Only one patient had persistent thrombocytopenia for which interruption of treatment was required. One patient had fatigue. There were no procedure-related complications. Six patients received only 1 or 2 administrations because of rapid disease progression within the first two months. Among the remainders, 4 patients had 6 and 1 had 11administrations. When evaluatde by RECIST criteria one patient had a complete remisson, two patients had a partial remission and 2 patients remained stable for at least 6 months. Conclusions: In this retrospective analysis intrahepatic administration of MMC was well tolerated and provided clincal benefit (respons or at least disease stabilization for 6 months) in 45% of heavily pre-treated patients. This treatment represents a valid therapeutic option for patients with predominant liver metastases of breast cancer after failure of standard systemic treatment. No significant financial relationships to disclose.
Phase I-II study of IV vinorelbine (VRL) and oxaliplatin (OXP) every two weeks (q2w) in metastatic breast cancer (MBC): Results of the phase I trial
Authors: Rodriguez-Lescure A. , Llombart A. , Colomer R. , Gutierrez G. , Gayo J. , Tusquets I. 
Published: March 2020

10691 Background: The combination of VRL and OXP was shown to be effective for the treatment of NSCLC. We designed a scheme for first line MBC consisting of administering IV VRL and OXP q2w to explore potential synergistic effects, to determine the maximal tolerated dose (MTD), recommended doses (RDs) and safety of the combination. Methods: Twelve patients (pts) entered the study. Four dose levels were established: A) VRL 25 mg/m2 with OXP 80 mg/m2, B) 25/90, C) 25/100 and D) 30/90, both drugs q2w. Patients/cycles analyzed were: A) 3/15, B) 3/21, C) 3/15, D) 3/19. Results: Median age 58 y (range; 39–78), 10 pts (83%) received prior (neo)adjuvant CT. No dose limiting toxicities were found at any of the dose levels. RD was established at IV VRL 30 mg/m2 and OXP 90 mg/m2/d both administered every 2 weeks. A total of 71 cycles were analyzed. Grade 3 neutropenia occurred in 4 pts (44%) and 13% of cycles, grade 4 in 1 pt (11%) and 1% of cycles. No complications were observed. No grade 4 non-haematological toxicity was seen. Grade 3 neurotoxicity occurred in 1 pt and 2 cycles, grade 3 fatigue occurred in 1 pt and 3 cycles. 2 partial responses were observed among the 6 evaluable patients for response. Conclusions: The combination of VRL and OXP is safe in the palliative setting of MBC. Phase II study explores the efficacy and safety of the combination of VRL 30 mg/m2 and OXP 90 mg/m2 q2w. Recruitment is ongoing. No significant financial relationships to disclose.